PASG vs PCSA

Passage Bio, Inc. vs Processa Pharmaceuticals, Inc. — Valuation Comparison 2026

PASG

Biotechnology
Passage Bio, Inc.
Quality
3.9
out of 10
Value Trap
24
SAFE
Price
$5.71
Last close
Models
7/13
Active
VS

PCSA

Biotechnology
Processa Pharmaceuticals, Inc.
Quality
3.7
out of 10
Value Trap
24
SAFE
Price
$2.64
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType PASG Fair ValuePASG Upside PCSA Fair ValuePCSA Upside
Bayesian DCF Intrinsic $3.83 -33.0% $1.04 -60.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $17.46 +205.7% $0.20 -93.4%
Dynamic NAV Asset-Based $30.86 +440.5% $5.65 +114.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PASG vs PCSA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PASG vs PCSA — Which Stock Is More Undervalued?

PASG scores higher with a 3.9/10 quality rating vs PCSA's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Passage Bio, Inc. (PASG) and Processa Pharmaceuticals, Inc. (PCSA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PASG currently trades at $5.71 with a QOC of 3.9/10, while PCSA trades at $2.64 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).